CMV 7-month data shows all GMT measures at or above CMV seropositive baselines; pivotal Phase 3 study of at least 8,000 participants expected to begin in 2021
First interim analysis of Phase 1 RSV vaccine candidate (mRNA-1345) shows >11- fold increase in RSV neutralizing antibodies in younger adults (ages 18-49 years); both 50 μg and 100 μg dose levels generally well-tolerated
Phase 1 clinical study of mRNA flu vaccine candidate expected to begin in 2021
Phase 1 study evaluating HIV mRNA vaccines with novel strategy expected to begin in 2021
Company provided update on its COVID-19 Vaccine program on April 13
Vaccines Day to be held on Wednesday, April 14 at 8:00 a.m. ET
https://finance.yahoo.com/news/moderna-announces-clinical-progress-industry-104500013.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.